Qiagen N.V. (NYSE:QGEN) Morgan Stanley twenty third Annual World Healthcare Convention September 9, 2025 1:05 PM EDT
Firm Individuals
Roland Sackers – CFO, MD & Member of Administration BoardJohn Gilardi – VP & Head of Company Communications
Convention Name Individuals
Aisyah Noor – Morgan Stanley, Analysis Division
Presentation
Aisyah NoorFairness Analyst
So thanks for becoming a member of us right this moment. My title is Aisyah Noor, European Medtech analyst with Morgan Stanley. I’ve with me on the stage, Mr. Roland Sackers, CFO of QIAGEN. And for the primary time in my profession with Morgan Stanley, Mr. John Gilardi, IR of QIAGEN. For analysis disclosures, please test morganstanley.com/researchdisclosures. However, sure, let’s begin.
Query-and-Reply Session
Aisyah NoorMorgan Stanley, Analysis Division
Thanks, everybody, for being right here right this moment. Roland, for the good thing about traders, may you type of present a recap of your current second quarter earnings?
Roland SackersCFO, MD & Member of Administration Board
Comfortable to take action, and thanks for having us. I’d clearly state that QIAGEN total had an excellent begin into the yr. We had an excellent progress price, not solely within the first quarter, but additionally the second quarter got here in with a 6% total progress price, which I do assume, significantly given the times, that are a bit extra risky, for those who assume on the tutorial franchise right here in U.S. and even on China, exhibits the energy of our total enterprise.
I do assume it is very clearly additionally attributed to the truth that 85%/90% of our total enterprise is a consumer-related enterprise. So we’re clearly a part of each day operations in all totally different buyer teams. Simply as a recap, 50% of our revenues go to the scientific settings, lab organizations; 50% go in what we name life science, together with pharma and utilized testing prospects.
The realm
